NCT04090086

A Study to Assess Interaction Between JNJ-64417184 and JNJ-53718678 After Single and Multiple Dosing in Healthy Participants

A Phase 1, Open-label, Randomized, 3-way Crossover Study to Assess the Pharmacokinetic Interaction Between JNJ-64417184 and JNJ-53718678 After Single and Multiple Dosing in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Janssen Research & Development, LLC · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the effect of single and multiple dose (once daily for 7 days) oral JNJ-64417184 and JNJ-53718678 on the pharmacokinetic (PK) of single and multiple-dose (once daily for 7 days) oral JNJ 53718678 and JNJ-64417184, respectively when coadministered to healthy adult participants under fed conditions.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	JNJ-53718678	JNJ-53718678 suspension will be administered orally as per assigned treatment sequence.
DRUG	JNJ-64417184	JNJ-64417184 tablet will be administered orally as per assigned treatment sequence.

Timeline

• Start date: 2019-09-16
• Primary completion: 2019-12-10
• Completion: 2019-12-10
• First posted: 2019-09-16
• Last updated: 2025-02-03

Locations

1 site across 1 country: Netherlands